The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), a new drug-device combination ...

Bradycardia, a slow resting heart rate, is healthy for elite athletes — but it can be dangerous if not caused by exercise ...

1 in every 3 deaths is linked to heart-related diseases Lifestyle-related risk factors account for 80% of years lost to death or disability THURSDAY, Sept. 25, 2025 (HealthDay News) — Heart disease ...

CINCINNATI (WKRC) - The Christ Hospital is introducing a mobile heart unit that offers low-cost screenings to help individuals assess their risk for heart attack or stroke. The initiative aims to ...

Edema and fluid overload remain the leading causes of hospitalization and readmission for patients with CHF, cirrhosis, and chronic kidney disease. An estimated 6.7 million Americans live with heart ...

Share on Pinterest Maintaining high blood potassium levels, for instance, by taking supplements, may help lower heart failure risk. Image credit: Viktoriya Skorikova/Getty Images A new trial ...

Chest pain and shortness of breath are two symptoms that grab your attention quickly, potentially signaling a heart attack if they come on suddenly. And if they develop gradually and worsen over time, ...

Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) ...

A commonly prescribed drug could be more effective than aspirin for long-term heart disease prevention. Analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests the blood thinner ...

The Apple Watch is on the wrist of millions of users across the world. Over the years, Apple has developed algorithms that collect data from the integrated PPG sensor to sense irregular heart rhythms ...

Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet Merck (NYSE: MRK) ...